Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Randomized Double-Blind Placebo-Controlled Study of Tirzepatide in NASH
2019-001550-26Phase 2Unknown
- Sponsor
- Eli Lilly and Company
- Start
- Dec 2019
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of tirzepatide in metabolic dysfunction-associated steatohepatitis (MASH) (4 arms), sponsored by Eli Lilly and Company. Primary endpoint: NASH resolution without worsening of fibrosis at Week 52. Status: unknown.
02
Drugs
03
Conditions
metabolic dysfunction-associated steatohepatitis (MASH)
Beyond the preview
Go deeper on 2019-001550-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-001550-26.